Irvine, Calif.-based Lombard Medical Inc. (NASDAQ: EVAR) has hit the pause button on its U.S. operations, company executives confirmed this week, citing an unexpected roadblock erected by the FDA. In addition, Lombard, which focuses on the minimally invasive treatment of abdominal aortic aneurysms (AAAs), is mulling strategic alternatives, including a sale.